These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20463405)

  • 1. Rethinking Alzheimer's disease therapy: are mitochondria the key?
    Ankarcrona M; Mangialasche F; Winblad B
    J Alzheimers Dis; 2010; 20 Suppl 2():S579-90. PubMed ID: 20463405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of mitochondrial amyloid-beta in Alzheimer's disease.
    Chen JX; Yan SS
    J Alzheimers Dis; 2010; 20 Suppl 2():S569-78. PubMed ID: 20463403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease.
    Atamna H; Frey WH
    Mitochondrion; 2007 Sep; 7(5):297-310. PubMed ID: 17625988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacogenomics of Alzheimer's disease.
    Crentsil V
    Ageing Res Rev; 2004 Apr; 3(2):153-69. PubMed ID: 15177052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are mitochondria critical in the pathogenesis of Alzheimer's disease?
    Reddy PH; Beal MF
    Brain Res Brain Res Rev; 2005 Nov; 49(3):618-32. PubMed ID: 16269322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease.
    Hung CH; Ho YS; Chang RC
    Ageing Res Rev; 2010 Oct; 9(4):447-56. PubMed ID: 20553970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches.
    Hake AM
    Semin Neurol; 2002 Mar; 22(1):71-4. PubMed ID: 12170395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
    Roy S; Rauk A
    Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
    Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F
    Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease.
    Aliev G; Palacios HH; Walrafen B; Lipsitt AE; Obrenovich ME; Morales L
    Int J Biochem Cell Biol; 2009 Oct; 41(10):1989-2004. PubMed ID: 19703659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease.
    Aliyev A; Chen SG; Seyidova D; Smith MA; Perry G; de la Torre J; Aliev G
    J Neurol Sci; 2005 Mar; 229-230():285-92. PubMed ID: 15760652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for apoptosis in Alzheimer's disease.
    Ankarcrona M; Winblad B
    Int J Geriatr Psychiatry; 2005 Feb; 20(2):101-5. PubMed ID: 15660410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.
    Fan LY; Chiu MJ
    Acta Neurol Taiwan; 2010 Dec; 19(4):228-45. PubMed ID: 21213151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
    Omerovic M; Hampel H; Teipel SJ; Buerger K
    World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease.
    Cardoso SM; Pereira CF; Moreira PI; Arduino DM; Esteves AR; Oliveira CR
    Exp Neurol; 2010 Jun; 223(2):294-8. PubMed ID: 19559703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase.
    Atamna H; Kumar R
    J Alzheimers Dis; 2010; 20 Suppl 2():S439-52. PubMed ID: 20463399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial aging and dysfunction in Alzheimer's disease.
    Sullivan PG; Brown MR
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):407-10. PubMed ID: 15795049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic and glutamatergic drugs in Alzheimer's disease therapy.
    Clarke NA; Francis PT
    Expert Rev Neurother; 2005 Sep; 5(5):671-82. PubMed ID: 16162091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial biology in Alzheimer's disease pathogenesis.
    Galindo MF; Ikuta I; Zhu X; Casadesus G; Jordán J
    J Neurochem; 2010 Aug; 114(4):933-45. PubMed ID: 20492350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
    Munoz L; Ammit AJ
    Neuropharmacology; 2010 Mar; 58(3):561-8. PubMed ID: 19951717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.